Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis.
The effect of recombinant desulphatohirudin CGP 39393 (rH) on arterial thrombus formation and especially on thrombotic reocclusion after experimental angioplasty as well as after thrombolysis was investigated in rabbits. In the femoral artery thrombi were induced after endothelial damage of the vessel wall by a balloon catheter and following stasis. After removing the thrombus by angioplasty or after lysing it by streptokinase reocclusion of the artery was observed within a relatively short period of time. Subcutaneous injection of rH reduced the incidence of both primary thrombus formation and reocclusion in dependence on the dose administered. After a dose of rH of 2 mg/kg s.c. arterial thrombus formation was completely prevented and after administering 4 mg/kg s.c. thrombotic reocclusion did also not occur. Comparative studies with heparin showed that similar antithrombotic effects were only achieved at doses of 12 mg heparin/kg s.c. The results obtained suggest a clear potential of rH for prevention of thrombotic reocclusion in clinical states.
Kaiser
B
B
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, GDR.
Simon
A
A
Markwardt
F
F
D000800:Angioplasty, Balloon; D000818:Animals; D005260:Female; D005263:Femoral Artery; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008297:Male; D011817:Rabbits; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D012008:Recurrence; D013300:Streptokinase / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D006629:Hirudins; D011994:Recombinant Proteins; D013300:Streptokinase; C060225:desirudin